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Abstract
Objective: Complex regional pain syndrome (CRPS) is a complication after surgery or trauma and is
characterized by a continuing regional pain in a distal extremity. The pain is disproportionate in
severity and duration in relation to the preceding trauma. Currently, the diagnosis is based on the
patients’ signs and symptoms. There is no objective clinically applicable test available to conﬁrm the
diagnosis of CRPS, however this could contribute to amore reliable and valid diagnosis. Since the
treatment of CRPS differs from that of other types of pain this could thereby lead to earlier and (more)
appropriate treatment and possibly to lowermedical costs. TheAeonose™ is a diagnostic test device
which detects volatile organic proﬁles in exhaled air. Exhaled breath analysis using an electronic nose
has been successfully applied to differentiate between sick and healthy persons for various indications.
This studywas a feasibility study inwhichwe investigatedwhether the Aeonose™ is able tomeasure a
difference in the volatome of CRPS patients compared to the volatome of healthy controls.Design:
Prospective observational study. Setting: University Center for PainMedicine. Subjects: Adult patients
diagnosedwithCRPS according to the latest IASP criteria (n=36) andmatched healthy controls
(n=36).Methods: Breath proﬁles were sampled by breathing in and out through theAeonose™. Data
were compressed using a Tucker3-like solution and subsequently used for training an artiﬁcial neural
network together with the classiﬁcation ‘CRPS: Yes’ or ‘CRPS:No’. Cross-validationwas applied using
the leave-10%-outmethod.Results: Data of the 72 participants were analyzed, resulting in a sensitivity
of 83% (95%CI 67%–93%), speciﬁcity of 78% (95%CI 60%–89%), and an overall accuracy of 81%.
Conclusions: This study suggests that the Aeonose™ can possibly distinguish patients with CRPS from
healthy controls based on analysis of their volatome (MEC-2014-149).
Introduction
Complex regional pain syndrome (CRPS) is character-
ized by a continuing regional pain, often combined
with vasomotor, sudomotor and motor/trophic dis-
turbances, in a distal extremity. Although inmost cases
the syndrome is preceded by a fracture, CRPS can also
be preceded by sprains, contusions, crush injuries or
surgery. The pain is disproportionate in severity and
duration in relation to the preceding trauma [1]. In a
part of the patients CRPS can have a serious course
with development of severe disability. The estimated
incidence of CRPS is 20–26.6 per 100.000 person
years [2, 3].
As no objective (laboratory) test is available to
diagnose CRPS, its diagnosis is based on the patients’
signs and symptoms [4]. To this end the Budapest cri-
teria are used [4], which have been updated according
to the latest IASP criteria [5]. An objective laboratory
test for the diagnosis of CRPS could contribute to a
more reliable and valid diagnosis of CRPS. Moreover,
since the treatment of CRPS differs from that of other
types of pain, misdiagnosis can lead to a delay in more
appropriate treatment and (consequently) to higher
medical costs [5].
Several studies have indicated that CRPS is an
auto-inﬂammatory disease [6–10]. Especially in
patients with acute CRPS, ‘classic’ signs of inﬂamma-
tion (e.g. pain, redness, swelling, increase in temper-
ature asymmetry) and loss of function can be seen
[11]. Earlier research found increased levels of sIL2-R
in peripheral blood of patients with CRPS compared
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to healthy controls [7]. Interleukin-2 is a cytokine
involved in regulating activation, proliferation, and
survival of T-lymphocytes [12, 13]. In sarcoidosis, also
an auto-inﬂammatory disease, the measurement of
sIL2-R is already clinically used to estimate disease
activity [14]. The measurement is not disease speciﬁc
but is presumably helpful in decisions to treat the
patient with immune modulating drugs. The speciﬁc
role of sIL-2R in CRPS is currently under invest-
igation. Another inﬂammatory marker that is sup-
posed to play a role in the pathogenesis of both CRPS
and sarcoidosis is TNF-alpha [6, 9, 10, 15]. In patients
with sarcoidosis TNF-alpha was found together with
other inﬂammatory markers, IGF-1, PAI-1, TGF-
beta1 and VEGF in exhaled breath condensate using
an enzyme immunoassay [16, 17]. This was followed
by a study of Dragonieri et alwho showed that an elec-
tronic nose was able to distinguish between sarcoidosis
and healthy controls [18].
An electronic nose is a device that measures the
volatome. Some of these devices focus on detecting
speciﬁc gas components, while others investigate the
integrated breath proﬁle. The volatome consists of
volatile organic compounds (VOCs) and can be detec-
ted in exhaled breath. These can be either exogenous,
endogenous or microbial [19, 20]. Exogenous volatiles
consist of components produced after eating food,
components derived from smoking cigarettes, or
components inhaled from the external environment.
Endogenous volatiles originate from internal meta-
bolic production [21]. Microbial VOCs are produced
bymicroorganisms that populate the epithelium of the
mouth, intestines and lungs [20]. Endogenous and
microbial VOCs can be clinically interesting. Endo-
genous VOCs reﬂect the physiological status of an
individual while microbial VOCs can be an indication
of the pathogen present in an infection [22].
Earlier research showed that electronic noses were
not only able to distinguish sarcoidosis from healthy
controls. The electronic nose used in this study, the
Aeonose™ (The eNose Company, Zutphen, the Neth-
erlands) was earlier successful in distinguishing
between healthy controls and patients with tubercu-
losis [23] lung cancer [24] gastric cancer [25] and with
untreated histologically proven primary prostate car-
cinoma [26]. The Aeonose™was also successful in dis-
tinguishing COPDpatients with andwithout infection
[27] and in distinguishing head and neck cancer from
other types of cancer including lung, bladder and
colon carcinoma [28, 29].
The above results are sufﬁciently promising to
investigate whether an electronic nose might be useful
in diagnosing patients with CRPS. Hence, this study
examines the potential of an electronic nose to distin-
guish between patients with CRPS and healthy
controls.
Methods
Participants
Between October 2013 and April 2015 consecutive
outpatients, diagnosed with CRPS according to the
latest IASP criteria [5], were enrolled from the Center
for Pain Medicine (Erasmus University Medical Cen-
ter Rotterdam). Patients had to be aged18 years.
Healthy controls, also aged18 years, were recrui-
ted among hospital employees, medical students, or
companions of the patients. If the diagnosis CRPS had
ever been considered a possibility in their medical his-
tory theywere excluded from the study.
The patient group was pairwise matched with the
healthy controls based on gender and age (±5 years),
as both these can inﬂuence the volatome [30]. All par-
ticipants gave informed consent.
The protocol was approved by the Medical Ethics
Committee of the Erasmus MC University Medical
Center Rotterdam (MEC-2014-149) and the study was
performed in accordance with the Declaration of Hel-
sinki (amended version of 2008).
Data collection
For all participants, information was collected on
demographics, general medical history, medication
use, and whether or not they smoked or used coffee.
This information was collected because there might be
multiple confounders which can potentially inﬂuence
breath analysis, including tobacco use, cardiopulmon-
ary status and interference from other molecules [31].
For each patient, the signs and symptoms of CRPS
were recorded by taking a medical history followed by
a physical examination. For each patient we also
established (i) which extremity was affected, (ii) pain
intensity using a numerical rating scale (NRS-11) on
the day that the breath sample was taken, and (iii)
disease duration.
Participants were asked to breathe gently through
an electronic nose (the Aeonose™, The eNose Com-
pany, Zutphen, theNetherlands) for 5 min. A nose clip
was used to ensure that the participants could only
breathe through the device. All participants were asked
to refrain from drinking alcohol, coffee and smoking
for at least 1 h before the test.
Materials
The Aeonose™ has three semi-conducting metal-
oxide sensors that are guided through a temperature
proﬁle. These sensors differ in terms of surface
characteristics. VOCs in exhaled breath induce redox
reactions at the sensor surfaces, changing surface
conductivity. These changes in conductivity are
dependent on the VOCs, the temperature (dynamics),
and the sensor-surface properties. During a measure-
ment cycle, a breath pattern is recorded consisting of
over two-thousand conductivity values per sen-
sor [32].
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Statistical analysis
Descriptive statistics were used to determine the
frequency of the demographic and outcome para-
meters, and to describe measures of central tendency
and variability, depending on the shape of their
distribution. The Shapiro–Wilk test was used to
analyze whether or not these parameters were nor-
mally distributed. Differences between the two groups
in proportions of dichotomous variables were ana-
lyzed using Fisher’s exact test. Differences in contin-
uous variables were evaluated using the Mann-
Whitney U test if the parameter was not normally
distributed and a T-test if the parameter was normally
distributed. Analyses were performed with the IBM
SPSS Statistics 21 andαwas set at the 0.05 level.
Data from the breath samples were analyzed by
The eNose Company using a proprietary software
package (AethenaTM). Data were compressed using a
Tucker3-like solution [33], resulting in a vector of lim-
ited size per patient. These vectors were subsequently
used for training an artiﬁcial neural network (ANN).
An ANN reﬂects the ‘learning’ and ‘generalization’
abilities of the human neural architecture by a mathe-
matical representation. This approach is widely used
when the relationship between the variables is
unknownor is complex.
To build an algorithm that can predict for disease,
the ANN has ﬁrst to be trained using patient data and
classiﬁcations (diagnosis) [34]. In the present study,
the database consisted of breath proﬁles of the partici-
pants with an added label ‘CRPS: Yes’ or ‘CRPS:No’.
To enhance the ability of the algorithm to dis-
criminate between sick and healthy participants,
cross-validationwas applied using the ‘leave-10%-out’
cross-validation. Recently, Kort et al provided a more
detailed description of the processing and analysis of
breath samples using AethenaTM [35]. After cross-vali-
dation, the sensitivity, speciﬁcity, positive predictive
value (PPV) and negative predictive value (NPV) were
calculated. The results are presented in a scatterplot.
Results
Characteristics of the participants
For this study 72 persons were enrolled: 36 patients
and 36 healthy controls. Demographic information
and data on smoking and coffee consumption are
presented in table 1; no signiﬁcant differences were
found between the two groups. The percentage of
participants suffering from a comorbidity are shown
per category, subdivided by experimental group
(table 2). Signiﬁcant differences were found between
patients and healthy controls in proportions suffering
from cardiac, pulmonary, upper gastro-intestinal and
lower gastro-intestinal comorbidities. The percentages
of participants suffering from these comorbidities
were lower in the healthy control group than they were
in theCRPS group.
Data on the NRS score and the duration of CRPS
are listed in table 3. In 30 of the 36 patients, one extre-
mity was affected by CRPS and in six patients two or
more extremities were affected. Two patients had had
a limb amputation because of CRPS; these two
patients still suffer from CRPS in one or more other
extremities. The signs and symptoms of the patients
are presented in table 4.
In four patients, one or two signs and symptoms
were not assessable, resulting in missing data. There-
fore, the percentages of the signs and symptoms listed
in table 5 were calculated based on the total number of
patients in whom these signs and symptoms were
assessable. The use of medication prescribed for CRPS
was also registered (table 5).
Aeonose™ classiﬁcation results
The threshold above which participants were desig-
nated as CRPS patient group was set to 0.00 . This is
the threshold where the sum of speciﬁcity and
sensitivity was maximal. This led to eight healthy
controls and six patients being classiﬁed into the
wrong group, with a sensitivity of 83% (95% CI 67%–
93%), a speciﬁcity of 78% (95% CI 60%–89%), a PPV
of 79% (95% CI 62%–90%), and a NPV of 82% (95%
CI 65%–93%). The overall accuracy appeared to be
81%. Figure 1 presents the ROC-curve based on the
abovementioned sensitivity and speciﬁcity.
Discussion
The results of this study give a ﬁrst indication that the
Aeonose™ is able to distinguish between patients with
CRPS andhealthy controls.
The pathophysiology of CRPS is complex and
based on multiple mechanisms; any or a combination
of these mechanisms, including inﬂammation, may
inﬂuence the volatome. Studies on sarcoidosis have
shown that it is possible to identify inﬂammatorymar-
kers (e.g. TNF-alpha) in exhaled breath condensate
using an enzyme immunoassay [16, 17]. So the ability
of the Aeonose™ to distinguish patients with sarcoi-
dosis from healthy controls could (also) be due to the
inﬂuence of inﬂammation [18]. In this study the vola-
tome of CRPS patients was only compared with the
volatome of healthy controls. Therefore it is unclear
Table 1.Characteristics of patients and healthy controls.
Patients Healthy controls
n 36 36 p
Gender (female) 29 (81%) 29 (81%) 1.00
Age: yearsmed-
ian (IQR)
36.5 (54.0–23.5) 35.5 (53.0–23.25) 0.77
Smoking (yes) 9 (25%) 5 (14%) 0.37
Consumption of
coffee (yes)
26 (72%) 31 (86%) 0.25
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whether the Aeonose™ made a discrimination
between CRPS patients and healthy controls based on
something that is speciﬁc for CRPS and not on some-
thing that CRPS has in common with other (pain)
conditions. For example, with pain patients in general,
or for patients with an inﬂammatory disease or even
for patients in distress. The Aeonose™ misclassiﬁed
eight healthy controls and six patients. The mis-
classiﬁcation of patients could be due to the different
clinical stages of CRPS (acute, subacute, chronic).
Another explanation for misclassiﬁcation of
participants is that it is still unclear whether the Aeo-
nose™ is capable tomeasure disease speciﬁc.
Asmentioned above, CRPS is based on consensus-
derived criteria. Obviously, because a golden standard
validation criterion is missing, it is actually impossible
to determine whether the IASP diagnostic criteria set
or the—based on empirically obtained data—trained
algorithm yields a better predictive validity. So, in this
light analyzing the (mis) classiﬁcations using the
trained algorithm could lead to a better nosological
and etiological understanding of CRPS and subse-
quently to less over- or underdiagnosis. This would
then result in improved clinical communication and
better generalizability across research samples. In
addition, it would enable physicians less familiar with
the IASP criteria to diagnose CRPS. Hereby it could
lead to (more) appropriate treatment in an earlier
stage, better research (more comparative research
samples) and possibly to lowermedical costs.
Before the Aeonose™ can be used in clinical prac-
tice, research is needed to ﬁnd out whether or not the
Aeonose™ is able to distinguish between patients with
CRPS from patients with other diseases showing simi-
lar symptoms and signs, and/or similar underlying
pathophysiologic mechanisms, especially inﬂamma-
tion. Thereafter a validation study is required in which
the trained algorithm classiﬁes blinded samples. If the
Table 2.Comorbidities of participants per category.
Category of comorbidities Number of patients (N=36) Number of healthy controls (N=36) P-value
Cardiac 9 (25%) 2 (5.6%) 0.046
Vascular 11 (31%) 7 (19.4%) 0.41
Hematopoietic 4 (11%) 1 (2.8%) 0.36
Respiratory 12 (33%) 3 (8.3%) 0.02
Eyes, ears, nose, throat, larynx 10 (28%) 4 (11.1%) 0.14
Upper gastro-intestinal 12 (33%) 4 (11.1%) 0.045
Lower gastro-intestinal 10 (28%) 0 (0%) 0.001
Liver, gall, pancreas 2 (6%) 2 (5.6%) 1.000
Kidneys 4 (11%) 1 (2.8%) 0.36
Urogenital 8 (22%) 4 (11.1%) 0.34
Muscle, bone, skin 9 (25%) 7 (19.4%) 0.78
Neurology 8 (22%) 5 (13.9%) 0.54
Endocrine/metabolic 5 (14%) 1 (2.8%) 0.20
Psychiatry 1 (3%) 2 (5.6%) 1.000
Table 3.Patients characteristics.
Patients
Duration of CRPS inmonths;median (IQR) 49.0 (79.0–20.00)
NRS-pain (scale 0–10)median (IQR) 7.0 (8.0–4.0)
Table 4. Symptoms and signs (N=36).
Symptoms Signs
Sensory
Allodynia 32 (89%) 30 (83%)
Hyper-/hypoesthesia 36 (100%) 34 (94%)
Vasomotor
Asymmetry in
temperature
32 (89%) 29 (81%)
Asymmetry in color 33 (92%) 31 (86%)
Sudomotor
Edema 30 (83%) 22 (61%)
Asymmetry in
sweating
30 (83%) 20 (56%)
Motor/trophic
Weakness 32 (89%) 27 (82%) (N=33)
Decreased range of
motion
28 (78%) 26 (74%) (N=35)
Dystonia or tremor 29 (81%) 8 (22%)
Change in hair
growth
19 (53%) 15 (42%)
Change in nail
growth
21 (58%) 17 (47%)
Skin atrophy 16 (46%) (N=35) 15 (42%)
Table 5.CRPS-relatedmedication use at the time of examining the
breath sample.
No. of patients
NSAID 6 (17%)
Opiates 16 (44%)
Co-analgesics (group of antidepressants) 7 (19%)
Co-analgesics (group op anti-epileptic drugs) 9 (25%)
Other painmedication 4 (11%)
Anti-oxidants 6 (17%)
Vasodilators 1 (3%)
Benzodiazepines 3 (8%)
Ketanserin 4 (11%)
Acetyl-L-carnitine 4 (11%)
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results of such a study show that the Aeonose™ is able
to differentiate CRPS patients from the above men-
tioned patient populations then we will have convin-
cing scientiﬁc evidence of using the Aeonose™ in
clinical practice.
Study limitations
Shirasu and Touhara demonstrated that the human
volatome varies by age, lifestyle, gender, physiological
status, and (possibly) by genetic background [30].
Therefore those parameters should be comparable in
the experimental and the control group. In the present
study, the two groups were pairwise matched only by
age and gender and no signiﬁcant differences in
smoking habits and/or coffee consumption were
found between the groups. Nevertheless, a limitation
of this study could be the fact that the two groups were
matched only on the parametersmentioned above and
not on other parameters such as physiological status
and genetic background. According to the study of
Shirasu and Touhara these aspects also affect the
volatome [30]. It would have been better to correct for
these aspects as well, but it is unclear what they exactly
mean by physiological status and genetic background.
Participants were asked to refrain from drinking
alcohol, coffee and smoking one hour before the
breath sample was taken. Two patients and two
healthy controls have not fulﬁlled this requirement.
There was no limit imposed on eating or drinking in
general. So far it has never been investigated whether
the absence of a period of refrainment affects the
classiﬁcation of the participants by the AeonoseTM,
nor has been investigated how long the period of
refrainment should be to prevent this. Hypothetically
the absence of a period of refrainment on eating and
drinking in general could possibly affects the classiﬁca-
tion. Besides that it is questionable if the hour of
refrainment of drinking alcohol, coffee and smoking
that was held in this study was long enough to prevent
bias of drinking alcohol, coffee or smoking on the
classiﬁcation. Moreover, signiﬁcant differences were
found between the patients and healthy controls in
cardiac, pulmonary, upper gastro-intestinal and lower
gastro-intestinal comorbidities, whichmay have inﬂu-
enced the results. Furthermore, some signiﬁcant
differences may be due to multiple comparison. We
have not corrected for this, which means that there is
an increased change of a type I error. Another
explanation for the signiﬁcant differences we found
could be that a medical history of asthma, migraine
and osteoporosis is associated with CRPS. The higher
percentage of pulmonary comorbidities that were
found in the CRPS group conﬁrms the ﬁnding of de
Mos et al [36]. The higher percentage of gastro-
intestinal comorbidities could be caused by use of
analgesics and co-analgesics in theCRPS group.
In this studywe found a sensitivity of 83% (95%CI
67%–93%), a speciﬁcity of 78% (95%CI 60%–89%), a
PPV of 79% (95%CI 62%–90%), a NPV of 82% (95%
CI 65%–93%). The appreciation of these measures of
the predictive validity is dependent on the prevalence
of a disease in the studied population—in our study
50%. Therefore, it would be useful to investigate whe-
ther a high validity would also be found in a study in
the general population
Conclusion
The volatome of 72 participants was analyzed with the
objective to investigate whether the Aeonose™ is able
to distinguish patients with CRPS from healthy
controls, resulting in a sensitivity of 83% (95% CI
67%–93%), speciﬁcity of 78% (95% CI 60%–89%),
and an overall accuracy of 81%. The patients were
diagnosed with CRPS using the IASP diagnostic
criteria set, which consists of consensus-derived
criteria. The two groups were pairwise matched based
Figure 1.Receiver operating characteristics curve of the Aeonose™ as a predictor of group (CRPSpatients versus healthy controls).
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on age and gender. There was no signiﬁcant difference
in smoking habits or coffee consumption. Limitations
of this study are that we did not correct for lifestyle,
physiological status and genetic background, that the
percentage of cardiac, pulmonary and gastro-intest-
inal comorbidities were signiﬁcant different between
the patients and healthy controls and that although
patients were asked to refrain from drinking alcohol,
coffee and smoking one hour before the breath sample
was taken, there was no period of refrainment on
eating and drinking in general. The results of this study
suggest that the Aeonose™ can possibly be used to
distinguish between CRPS patients and healthy con-
trols based on analysis of their volatome. Further
validation steps are necessary to establish the value of
the AeonoseTM in the differential diagnostic process
of CRPS.
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